161 related articles for article (PubMed ID: 37699572)
1. Fluorescence Lifetime Nanoscopy of Liposomal Irinotecan Onivyde: From Manufacturing to Intracellular Processing.
Bernardi M; Signore G; Moscardini A; Pugliese LA; Pesce L; Beltram F; Cardarelli F
ACS Appl Bio Mater; 2023 Oct; 6(10):4277-4289. PubMed ID: 37699572
[TBL] [Abstract][Full Text] [Related]
2. Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer.
Liu X; Jiang J; Chan R; Ji Y; Lu J; Liao YP; Okene M; Lin J; Lin P; Chang CH; Wang X; Tang I; Zheng E; Qiu W; Wainberg ZA; Nel AE; Meng H
ACS Nano; 2019 Jan; 13(1):38-53. PubMed ID: 30525443
[TBL] [Abstract][Full Text] [Related]
3. Phasor-FLIM-guided unraveling of ATRA supramolecular organization in liposomal nanoformulations.
Bernardi M; Vernizzi M; Baraldi L; Balog S; Bassanetti I; Sgarbi E; Fornasari L; Arrigoni C; Cardarelli F
Nanoscale; 2023 Dec; 15(47):19085-19090. PubMed ID: 37991853
[TBL] [Abstract][Full Text] [Related]
4. Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Milano G; Innocenti F; Minami H
Cancer Sci; 2022 Jul; 113(7):2224-2231. PubMed ID: 35445479
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with Onivyde for pancreatic cancer.
Wang X; Liu Y; Xu W; Jia L; Chi D; Yu J; Wang J; He Z; Liu X; Wang Y
Drug Deliv Transl Res; 2021 Oct; 11(5):2186-2197. PubMed ID: 33452654
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence lifetime microscopy unveils the supramolecular organization of liposomal Doxorubicin.
Tentori P; Signore G; Camposeo A; Carretta A; Ferri G; Pingue P; Luin S; Pozzi D; Gratton E; Beltram F; Caracciolo G; Cardarelli F
Nanoscale; 2022 Jun; 14(25):8901-8905. PubMed ID: 35719059
[TBL] [Abstract][Full Text] [Related]
7. Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition.
Moloney C; Roy Chaudhuri T; Spernyak JA; Straubinger RM; Brougham DF
Acta Biomater; 2023 Mar; 158():611-624. PubMed ID: 36603732
[TBL] [Abstract][Full Text] [Related]
8. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Lamb YN; Scott LJ
Drugs; 2017 May; 77(7):785-792. PubMed ID: 28401446
[TBL] [Abstract][Full Text] [Related]
9. Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
Bernards N; Ventura M; Fricke IB; Hendriks BS; Fitzgerald J; Lee H; Zheng J
Mol Pharm; 2018 Sep; 15(9):4132-4138. PubMed ID: 30059232
[TBL] [Abstract][Full Text] [Related]
10. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
Yang W; Yang Z; Fu J; Guo M; Sun B; Wei W; Liu D; Liu H
Biomater Sci; 2018 Dec; 7(1):419-428. PubMed ID: 30500018
[TBL] [Abstract][Full Text] [Related]
11. Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation.
Yang W; Yang Z; Liu J; Liu D; Wang Y
Asian J Pharm Sci; 2019 Nov; 14(6):687-697. PubMed ID: 32104495
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Passero FC; Grapsa D; Syrigos KN; Saif MW
Expert Rev Anticancer Ther; 2016 Jul; 16(7):697-703. PubMed ID: 27219482
[TBL] [Abstract][Full Text] [Related]
13. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery.
Caracciolo G; Palchetti S; Digiacomo L; Chiozzi RZZ; Capriotti AL; Amenitsch H; Tentori PM; Palmieri V; Papi M; Cardarelli F; Pozzi D; Laganà A
ACS Appl Mater Interfaces; 2018 Jul; 10(27):22951-22962. PubMed ID: 29905462
[TBL] [Abstract][Full Text] [Related]
14. Effect of Glucose on Liposome-Plasma Protein Interactions: Relevance for the Physiological Response of Clinically Approved Liposomal Formulations.
Palchetti S; Digiacomo L; Pozzi D; Zenezini Chiozzi R; Capriotti AL; Laganà A; Coppola R; Caputo D; Sharifzadeh M; Mahmoudi M; Caracciolo G
Adv Biosyst; 2019 Feb; 3(2):e1800221. PubMed ID: 32627369
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia.
Ventura M; Bernards N; De Souza R; Fricke IB; Hendriks BS; Fitzgerald JB; Lee H; Klinz SG; Zheng J
Mol Imaging Biol; 2020 Jun; 22(3):653-664. PubMed ID: 31482415
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.
Brendel K; Bekaii-Saab T; Boland PM; Dayyani F; Dean A; Macarulla T; Maxwell F; Mody K; Pedret-Dunn A; Wainberg ZA; Zhang B
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1550-1563. PubMed ID: 34750990
[TBL] [Abstract][Full Text] [Related]
17. Onivyde for the therapy of multiple solid tumors.
Zhang H
Onco Targets Ther; 2016; 9():3001-7. PubMed ID: 27284250
[TBL] [Abstract][Full Text] [Related]
18. Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells.
Papi M; Caputo D; Palmieri V; Coppola R; Palchetti S; Bugli F; Martini C; Digiacomo L; Pozzi D; Caracciolo G
Nanoscale; 2017 Jul; 9(29):10327-10334. PubMed ID: 28702661
[TBL] [Abstract][Full Text] [Related]
19. In brief: liposomal irinotecan (Onivyde) for pancreatic cancer.
Med Lett Drugs Ther; 2016 Jun; 58(1496):e76. PubMed ID: 27249099
[No Abstract] [Full Text] [Related]
20. Redox-sensitive irinotecan liposomes with active ultra-high loading and enhanced intracellular drug release.
Wang T; He W; Du Y; Wang J; Li X
Colloids Surf B Biointerfaces; 2021 Oct; 206():111967. PubMed ID: 34256270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
